Dynavax Technologies (DVAX) Stock Price, News & Analysis

Company Overview

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Key Stats

• Today's Range: $11.75 to $12.24
• 50-Day Range: $10.28 to $13.66
• 52-Week Range: $9.74 to $15.01
• Volume: 1.35 million shs
• Average Volume: 2.17 million shs
• Market Capitalization: $1.60 billion
• P/E Ratio: 93.62
• Dividend Yield: N/A
• Price Target: $22.00
• Consensus Rating: Moderate Buy

Dynavax Technologies Stock Analysis - MarketRank™

Dynavax Technologies scored higher than 93% of companies evaluated by MarketBeat, and ranked 90th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Dynavax Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Dynavax Technologies has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 52.63%

Earnings Growth

Earnings for Dynavax Technologies are expected to grow by 52.63% in the coming year, from $0.19 to $0.29 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Dynavax Technologies is 93.62, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 131.16.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dynavax Technologies is 93.62, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 126.31.

Price to Book Value per Share Ratio

Dynavax Technologies has a P/B Ratio of 2.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.33% of the outstanding shares of Dynavax Technologies have been sold short.

Short Interest Ratio / Days to Cover

Dynavax Technologies has a short interest ratio ("days to cover") of 9.

Change versus previous month

Short interest in Dynavax Technologies has recently increased by 10.43%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Dynavax Technologies does not currently pay a dividend.

Dividend Growth

Dynavax Technologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -1.59

Percentage of Shares Shorted

14.33% of the outstanding shares of Dynavax Technologies have been sold short.

Short Interest Ratio / Days to Cover

Dynavax Technologies has a short interest ratio ("days to cover") of 9.

Change versus previous month

Short interest in Dynavax Technologies has recently increased by 10.43%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.79

News Sentiment

Dynavax Technologies has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Dynavax Technologies this week, compared to 4 articles on an average week.

Search Interest

6 people have searched for DVAX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Dynavax Technologies to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Dynavax Technologies insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.98% of the stock of Dynavax Technologies is held by insiders.

Percentage Held by Institutions

96.96% of the stock of Dynavax Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DVAX Stock Analysis - Frequently Asked Questions

How have DVAX shares performed this year?

Dynavax Technologies' stock was trading at $13.98 on January 1st, 2024. Since then, DVAX stock has decreased by 12.9% and is now trading at $12.17.
View the best growth stocks for 2024 here.

How were Dynavax Technologies' earnings last quarter?

Dynavax Technologies Co. (NASDAQ:DVAX) issued its quarterly earnings data on Tuesday, August, 6th. The biopharmaceutical company reported $0.08 EPS for the quarter, topping analysts' consensus estimates of $0.06 by $0.02. The biopharmaceutical company had revenue of $73.80 million for the quarter, compared to the consensus estimate of $76.92 million. Dynavax Technologies had a trailing twelve-month return on equity of 3.19% and a net margin of 7.85%.

Who are Dynavax Technologies' major shareholders?

Top institutional investors of Dynavax Technologies include State Street Corp (5.85%), Chicago Capital LLC (4.19%), Geode Capital Management LLC (2.28%) and Mizuho Markets Americas LLC (1.05%). Insiders that own company stock include Andrew A F Hack, Ryan Spencer, Robert Janssen, Francis Cano, David F Novack and Justin Burgess.
View institutional ownership trends.

How do I buy shares of Dynavax Technologies?

Shares of DVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Dynavax Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Dynavax Technologies investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 8/06/2024
• Today: 11/20/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 2/27/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:DVAX
• CUSIP: 26815810
• CIK: 1029142
• Web: www.dynavax.com
• Phone: (510) 848-5100
• Fax: 510-848-1327
• Employees: 408
• Year Founded: 1996

Price Target and Rating

• Average Stock Price Target: $22.00
• High Stock Price Target: $29.00
• Low Stock Price Target: $15.00
• Potential Upside/Downside: +80.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.13
• Trailing P/E Ratio: 93.62
• Forward P/E Ratio: 64.05
• P/E Growth: N/A
• Net Income: $-6,390,000.00
• Net Margins: 7.85%
• Pretax Margin: 9.29%
• Return on Equity: 3.19%
• Return on Assets: 2.02%

Debt

• Debt-to-Equity Ratio: 0.33
• Current Ratio: 13.23
• Quick Ratio: 12.34

Sales & Book Value

• Annual Sales: $232.28 million
• Price / Sales: 6.89
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.81 per share
• Price / Book: 2.53

Miscellaneous

• Outstanding Shares: 131,460,000
• Free Float: 127,538,000
• Market Cap: $1.60 billion
• Optionable: Optionable
• Beta: 1.34